20S Proteasome Assay Kit

The proteasome is a multicatalytic proteinase complex that is involved in the selective degradation of intracellular proteins. The 20S proteasome is the proteolytic core particle of a large protein degradation complex, the 26S proteasome. Proteasome inhibitors exhibit anti-inflammatory and antiproliferative effects, evidence that the proteasome may be an important drug target for the treatment for cancer and inflammatory diseases. Cayman’s 20S Proteasome Assay Kit employs a specific 20S substrate, SUC-LLVY-AMC which, upon cleavage by the active enzyme, generates a highly fluorescent product with an emission wavelength at 480 nm. The kit is easy to use and can be easily adapted to high-throughput screening for therapeutic compounds regulating activation of the 20S proteasome.

Needed but not supplied: Please download the kit booklet to verify if UltraPure Water (Milli-Q or equivalent) or any other components are needed for this assay.

WARNING This product is not for human or veterinary use.

Zhao, Z., Lim, H.Y., Cannone, E., et al. CryAB-driven amyloidogenesis in Drosophila muscle engages extracellular vesicle pathways for cellular release. iScience 29(4), 115461 (2026).

Khurana, N., Kim, H., Chandra, P.K., et al. Multimodal actions of the phytochemical sulforaphane suppress both AR and AR-V7 in 22Rv1 cells: Advocating a potent pharmaceutical combination against castration-resistant prostate cancer. Oncol. Rep. 38(5), 2774-2786 (2017).

Yun, S.P., Kim, D., Kim, S., et al. a-Synuclein accumulation and GBA deficiency due to L444P GBA mutation contributes to MPTP-induced parkinsonism. Mol. Neurodegener. 13(1), (2018).

Kikuchi, J., Shibayama, N., Yamada, S., et al. Homopiperazine derivatives as a novel class of proteasome inhibitors with a unique mode of proteasome binding. PLoS One 8(4), e60649 (2013).